Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1Lung Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Neuroendocrine 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Breast Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paclitaxel 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Docetaxel × Endocrine × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡